on June 23. Despite a 20% year-to-date rally, Kasimov's price target nonetheless translates into sizable upside potential of 50%.
After hosting GWPH during the firm's 2020 Biotech Conference Call Series, Kasimov praised the stock's favorable set up, writing: "Our conversation with management highlighted numerous upside levers in the near-term and the mid- to long-term." For instance, GWPH's flagship product, cannabinoid Epidiolex has just enjoyed a very successful launch. However, it is still only less than 50% penetrated in Dravet and Lennox-Gastaut Syndrome, leaving ample opportunity for growth. That's as GWPH is gearing up for a potentially very profitable Epidiolex label expansion in Tuberous Sclerosis with a US regulatory decision set for July 31.
"Near-term label expansion opportunities and the potential for off-label use in the broader population of general epilepsy patients could contribute significantly to the top line" Kasimov writes. He also recommends keeping a close eye on the company's second drug, Sativex, a 'perhaps underappreciated potential revenue driver' for multiple sclerosis-related stiffness. In terms of analyst performance, Kasimov is ranked #123 out of over 6,700 analysts covered by TipRanks.
Shouldn’t MasterCard be concerned about a wave of defaults?
wow i had no idea Q2 meant 4 YEARS later. stockmarketbubble2020
I second that!
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Fuente: latimes - 🏆 11. / 82 Leer más »
Fuente: latimes - 🏆 11. / 82 Leer más »